药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Trastuzumab deruxtecan.
Difenoxin
Opicinumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Opicinumab.
Difenoxin
Pamrevlumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Pamrevlumab.
Difenoxin
Bermekimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bermekimab.
Difenoxin
Rozanolixizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Rozanolixizumab.
Difenoxin
Refanezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Refanezumab.
Difenoxin
Bevacizumab zirconium Zr-89
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bevacizumab zirconium Zr-89.
Difenoxin
Emactuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emactuzumab.
Difenoxin
Parsatuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Parsatuzumab.
Difenoxin
Vobarilizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Vobarilizumab.
Difenoxin
Lintuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lintuzumab.
Difenoxin
Xentuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Xentuzumab.
Difenoxin
Brolucizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Brolucizumab.
Difenoxin
Codrituzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Codrituzumab.
Difenoxin
Icrucumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Icrucumab.
Difenoxin
Isatuximab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Isatuximab.
Difenoxin
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Anetumab ravtansine.
Difenoxin
Gancotamab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Gancotamab.
Difenoxin
Setrusumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Setrusumab.
Difenoxin
Camrelizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Camrelizumab.